• Fibrocell Announces FDA Fast Track Designation of FCX-013 americanpharmaceuticalreview
    September 06, 2018
    Fibrocell Science announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to FCX-013, the Company’s clinical stage candidate for the treatment of moderate to severe localized scleroderma, a chronic, debilitating genet
PharmaSources Customer Service